Lung cancer trial: can radiation boost targeted drugs for limited metastases?

NCT ID NCT05277844

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase II trial is for people with a specific type of non-small cell lung cancer that has spread to only a few places in the body (oligometastatic) and has a driver mutation like EGFR or ALK. Participants have already been on a targeted therapy pill (TKI) for 2-4 months without their cancer getting worse. Half will continue TKI alone, and the other half will also receive radiation to all known cancer spots. The study aims to see if adding radiation delays cancer progression and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tyrosine kinase inhibitor (TKI) and local consolidative radiation therapy

What this could lead to

If successful, this could show that adding radiation to standard TKI therapy helps control cancer spread and delays progression in patients with a limited number of metastases.

What could go wrong

This is a phase II trial with only 106 participants, so results are preliminary. Adding radiation may increase side effects without improving survival, and the benefit may not apply to all mutation types.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tata Memorial Hospital

    RECRUITING

    Mumbai, Maharashtra, 400012, India

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact